In this article, we will take a look at the 10 Best Breakout Stocks To Invest In Right Now.

Since 1950, the S&P 500 has posted at least a 15% gain through September on 17 occasions. In those years, the index rose a median of 5.4% in the fourth quarter and ended the year with gains in all but three instances, according to Keith Lerner, co-chief investment officer at Truist Advisory Services. Strong gains in U.S. stocks this year suggest a positive outlook for the remainder of 2024, if historical trends hold.

The S&P 500 is currently up 20% year-to-date, nearing a record high and poised for its best January-to-September performance since 1997. Optimism around a potential ‘soft landing’ has fueled this rally, alongside a recent 50 basis point rate cut by the central bank.

Overall, inflation in the U.S. is steadily nearing the Federal Reserve’s 2% annual target. Analysts suggest that the ongoing moderation in consumer prices could prompt further interest rate cuts to prevent a spike in unemployment. The personal consumption expenditures price index, a key inflation measure monitored by the Fed, increased by just 0.1% in the past month. This brings the 12-month inflation rate to 2.2%, down from 2.5% in July, marking its lowest level since February 2021. Moreover, Fed officials have seem to have shifted their focus from combating inflation to prioritizing support for a labor market showing signs of slowing. During their recent meeting, policymakers signaled the possibility of a half-percentage-point cut this year, followed by a full-point reduction in 2025.

That said, the current financial landscape reflects the Fed’s cautious strategy to engineer a soft landing for the economy—curbing inflation without inducing a recession. Gregory Daco, Chief Economist at EY-Parthenon, observes that the U.S. economy is gradually decelerating, with both consumers and businesses adopting more cautious spending behaviors due to a tightening labor market and rising costs. Although consumer spending hasn’t seen a sharp decline, Daco suggests that slower growth in disposable income could lead to more subdued spending in 2025. He projects consumer spending growth to slow to an average of 2.5% in Q4 2024, dropping further to 2% in 2025.

On another front, Mark Spitznagel, Chief Investment Officer and founder of Universa, believes the U.S. is on the brink of a significant downturn due to the high levels of debt and sustained high interest rates. “The clock is ticking, and we are entering black swan territory,” he told Reuters, warning that the recent “disinversion” of a key segment of the U.S. Treasury yield curve—a crucial recession indicator—signals an impending sharp downturn. Spitznagel anticipates a recession could hit as early as this year, prompting the Fed to slash rates aggressively from the current 4.75%-5% range and potentially returning to quantitative easing (QE), or bond buying.

Our Methodology

To compile our list of the best breakout stocks, we analyzed the holdings of the IBD Breakout Opportunities ETF and ranked them based on the number of hedge funds that initiated long positions in Q2 2024. From this group, we identified the top breakout stocks that are the most widely held by hedge funds.

At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

10. DaVita Inc. (NYSE:DVA)

Number of Hedge Fund Holders: 34

DaVita Inc. (NYSE:DVA) provides medical care services and is the leading provider of kidney dialysis services in the United States, operating 2,675 outpatient dialysis centers domestically and an additional 367 sites across 11 countries.

Despite operational challenges, DaVita Inc. (NYSE:DVA) has shown financial resilience. In August 2024, the company raised its EBIT guidance by $35 million, a 2% increase, despite incurring an extra $60 million in annual clinic expenses that were previously unaccounted for. Moreover, DaVita Inc. (NYSE:DVA) saw a 1.1% increase in dialysis treatments, reaching $7.265 million. The company reported revenues of $3.187 billion and a net income of $223 million, or $2.59 per share, and ended the quarter with a strong financial footing, generating $1 billion in free cash flow.

Analysts forecast DaVita’s earnings per share to be $9.77 for the current fiscal year, with an expected increase to $10.74 for the following year, indicating a promising outlook for the company’s profitability.

A review of 912 hedge fund portfolios by Insider Monkey for Q2 2024 found 34 investors with holdings in DaVita Inc. (NYSE:DVA). The largest stakeholder was Warren Buffett’s Berkshire Hathaway, with a $5 billion investment.

Here’s what Ariel Global Fund mentioned about DaVita Inc. (NYSE:DVA) in its Q1 2024 investor letter:

“Leading provider of dialysis services, DaVita Inc. (NYSE:DVA) outperformed during the period following a top- and bottom-line earnings beat. DaVita is benefitting from cost saving initiatives, early signs of a normalization in patient growth trends on par with pre-pandemic levels, improved leverage and an aggressive share buyback program. The company also recently announced an expansion of its international operations in Latin America, presenting an attractive long-term growth opportunity. Furthermore, management provided a 2024 financial outlook which is well above consensus and anticipates favorable growth. In our view, we believe the market misunderstands the long-term clinical impact of glucagon-like-peptide-1 (GLP-1s) on dialysis and as such, DaVita currently trades at a significant discount relative to our estimate of its intrinsic value.”

9. Axon Enterprise, Inc. (NASDAQ:AXON)

Number of Hedge Fund Holders: 36

Axon Enterprise, Inc. (NASDAQ:AXON) is a U.S.-based company that manufactures a range of products for law enforcement, military, and civilian markets, including TASER energy weapons, cameras, and sensors.

In the second quarter, Axon Enterprise, Inc. (NASDAQ:AXON) achieved record performance, with revenues exceeding $500 million and new business bookings surpassing $1 billion. This growth was propelled by the launch of new products such as the TASER 10 and Axon Body 4, along with a strategic shift toward software and services, which now make up 39% of total revenue. The company has raised its full-year revenue guidance to between $2 billion and $2.05 billion, supported by a future contracted revenue of approximately $7.4 billion.

Moreover, Baird recently reiterated its Outperform rating for AXON, increasing the stock’s price target to $400 from $360. The firm cited potential growth drivers such as new AI capabilities and emerging opportunities in the enterprise sector and drone technology. These prospects are expected to complement the strong performance of Axon’s core products and software offerings.

In the second quarter of 2024, 36 out of 912 hedge funds tracked by Insider Monkey held stakes in Axon Enterprise, Inc. (NASDAQ:AXON). The largest shareholder among them was Neil C. Bradsher’s Broadwood Capital, with 760,062 shares valued at $223.64 million.